January 16, 2015
RevMAb Biosciences USA, Inc has developed a revolutionary monoclonal antibody generation method which allows development of monoclonal antibodies without generation of hybridoma.
January 15, 2015
Sanbio signed an exclusive contract with ESI BIO, division of BioTime Inc. The breakthrough stem cell technologies, light the path from research to clinic in order to help our customers with their goal of treating disease.